HK1206335A1 - 具有抗腫瘤活性的色烯酮衍生物 - Google Patents

具有抗腫瘤活性的色烯酮衍生物

Info

Publication number
HK1206335A1
HK1206335A1 HK15106851.8A HK15106851A HK1206335A1 HK 1206335 A1 HK1206335 A1 HK 1206335A1 HK 15106851 A HK15106851 A HK 15106851A HK 1206335 A1 HK1206335 A1 HK 1206335A1
Authority
HK
Hong Kong
Prior art keywords
tumour activity
chromenone derivatives
chromenone
derivatives
tumour
Prior art date
Application number
HK15106851.8A
Other languages
English (en)
Inventor
Bernard Christophe Barlaam
Sebastien Louis Degorce
Christine Marie Paul Lambert-Van Der Brempt
Remy Robert Morgentin
Patrick Ple
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1206335A1 publication Critical patent/HK1206335A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74Benzo[b]pyrans, hydrogenated in the carbocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK15106851.8A 2009-10-27 2015-07-20 具有抗腫瘤活性的色烯酮衍生物 HK1206335A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09306017 2009-10-27

Publications (1)

Publication Number Publication Date
HK1206335A1 true HK1206335A1 (zh) 2016-01-08

Family

ID=43085922

Family Applications (2)

Application Number Title Priority Date Filing Date
HK13100967.4A HK1174027A1 (zh) 2009-10-27 2013-01-22 具有抗腫瘤活性的色烯酮衍生物
HK15106851.8A HK1206335A1 (zh) 2009-10-27 2015-07-20 具有抗腫瘤活性的色烯酮衍生物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK13100967.4A HK1174027A1 (zh) 2009-10-27 2013-01-22 具有抗腫瘤活性的色烯酮衍生物

Country Status (41)

Country Link
US (5) US8399460B2 (zh)
EP (1) EP2493870B1 (zh)
JP (2) JP5657010B2 (zh)
KR (1) KR101738195B1 (zh)
CN (2) CN104447657B (zh)
AR (1) AR078786A1 (zh)
AU (1) AU2010311107B9 (zh)
BR (1) BR112012010124B8 (zh)
CA (1) CA2776994C (zh)
CL (1) CL2012001056A1 (zh)
CO (1) CO6541528A2 (zh)
CR (1) CR20120217A (zh)
CU (1) CU20120069A7 (zh)
CY (1) CY1116143T1 (zh)
DK (1) DK2493870T3 (zh)
DO (1) DOP2012000124A (zh)
EA (1) EA020523B9 (zh)
EC (1) ECSP12011838A (zh)
ES (1) ES2530943T3 (zh)
GT (1) GT201200126A (zh)
HK (2) HK1174027A1 (zh)
HN (1) HN2012000889A (zh)
HR (1) HRP20150146T1 (zh)
IL (1) IL219191A0 (zh)
IN (1) IN2012DN03328A (zh)
ME (1) ME02050B (zh)
MX (1) MX2012005027A (zh)
MY (1) MY179833A (zh)
NI (1) NI201200081A (zh)
NZ (1) NZ599457A (zh)
PE (1) PE20130149A1 (zh)
PL (1) PL2493870T3 (zh)
PT (1) PT2493870E (zh)
RS (1) RS53813B1 (zh)
SA (1) SA110310808B1 (zh)
SI (1) SI2493870T1 (zh)
SM (1) SMT201500036B (zh)
TW (1) TWI483939B (zh)
UA (1) UA107474C2 (zh)
UY (1) UY32978A (zh)
WO (1) WO2011051704A1 (zh)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5599783B2 (ja) 2008-05-30 2014-10-01 アムジエン・インコーポレーテツド Pi3キナーゼの阻害薬
US8399460B2 (en) * 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
UY34013A (es) 2011-04-13 2012-11-30 Astrazeneca Ab ?compuestos de cromenona con actividad anti-tumoral?.
JP6307096B2 (ja) 2013-01-23 2018-04-04 アストラゼネカ アクチボラグ 化合物
CN105142629B (zh) * 2013-03-04 2018-11-23 阿斯利康(瑞典)有限公司 组合治疗
CA2952012A1 (en) 2014-06-13 2015-12-17 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
EA201692266A1 (ru) 2014-06-13 2017-06-30 Джилид Сайэнс, Инк. Ингибиторы фосфатидилинозитол-3-киназы
CA2952037A1 (en) 2014-06-13 2015-12-17 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
EP3154962B1 (en) 2014-06-13 2019-08-07 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
EA201692267A1 (ru) 2014-06-13 2017-06-30 Джилид Сайэнс, Инк. Ингибиторы фосфатидилинозитол-3-киназы
CN104744376A (zh) * 2015-03-14 2015-07-01 长沙深橙生物科技有限公司 一种2-异丙基嘧啶衍生物的制备方法
CN104803921A (zh) * 2015-03-14 2015-07-29 长沙深橙生物科技有限公司 一种苯取代嘧啶衍生物的制备方法
KR101766731B1 (ko) 2015-06-23 2017-08-10 충남대학교산학협력단 강심 활성을 갖는 크로메논 유도체 및 이를 포함하는 심부전의 예방 또는 치료용 약학 조성물
US10526316B2 (en) * 2015-10-09 2020-01-07 Janssen Pharmaceutica Nv Quinoxaline and pyridopyrazine derivatives as PI3Kβ inhibitors
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2018057808A1 (en) 2016-09-23 2018-03-29 Gilead Sciences, Inc. Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors
AR121719A1 (es) 2020-04-03 2022-06-29 Petra Pharma Corp Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
KR20210141214A (ko) * 2020-05-15 2021-11-23 제이투에이치바이오텍 (주) 3원환 화합물 및 이의 의약 용도
AU2022214080A1 (en) * 2021-02-01 2023-09-14 Geode Therapeutics Inc. Phosphoinositide 3 kinase beta inhibitors and compositions and methods thereof
AU2022269566A1 (en) * 2021-05-03 2023-11-02 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
IL307950A (en) * 2021-05-03 2023-12-01 Petra Pharma Corp Allosteric chromanone inhibitors of PHOSPHOINOSITIDE 3-KINASE (PI3K) for the treatment of diseases
BR112023022890A2 (pt) * 2021-05-27 2024-01-23 Petra Pharma Corp Inibidores de cromenona alostéricos de fosfoinositídio 3-cinase (pi3k), composições farmacêuticas que os compreendem e usos dos mesmos
CA3237760A1 (en) * 2021-12-08 2023-06-15 Xiaolin Hao Fused heterocyclic compounds as pi3kalpha inhibitors
WO2024003241A1 (en) 2022-06-30 2024-01-04 Astrazeneca Ab Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4
WO2024081904A1 (en) * 2022-10-14 2024-04-18 Genesis Therapeutics, Inc. Methods for treating cancer

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6027A (en) * 1849-01-09 Rotary blacksmith s twyer
AU634994B2 (en) 1988-12-21 1993-03-11 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
JPH05509302A (ja) 1990-06-20 1993-12-22 ジ・アップジョン・カンパニー 抗アテローム性動脈硬化性および抗血栓性1―ベンゾピラン―4―オン類および2―アミノ―1,3―ベンゾオキサジン―4―オン類
DE4318756A1 (de) 1993-06-05 1994-12-08 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
HUP9901155A3 (en) 1996-02-13 2003-04-28 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
KR100489174B1 (ko) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
CZ306810B6 (cs) 1999-02-10 2017-07-19 Astrazeneca Ab Použití chinazolinového derivátu jako inhibitoru angiogeneze
CA2398163C (en) 2000-01-24 2011-02-22 Kinacia Pty Ltd. Therapeutic morpholino-substituted compounds
KR20030013433A (ko) 2000-05-31 2003-02-14 아스트라제네카 아베 혈관 손상 활성을 가진 인돌 유도체
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
HUP0301742A3 (en) 2000-07-07 2005-08-29 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use
EP1301497A1 (en) 2000-07-07 2003-04-16 Angiogene Pharmaceuticals Limited Colchinol derivatives as vascular damaging agents
NZ538420A (en) * 2002-08-16 2007-06-29 Kinacia Pty Ltd Inhibition of phosphoinositide 3-kinase beta
AR054438A1 (es) * 2005-04-15 2007-06-27 Kudos Pharm Ltd Inhibidores de adn -pk
EP1957475A1 (en) 2005-10-21 2008-08-20 Merz Pharma GmbH & Co.KGaA Chromenones and their use as modulators of metabotropic glutamate receptors
CN101448505A (zh) * 2006-04-04 2009-06-03 加利福尼亚大学董事会 Pi3激酶拮抗剂
WO2008064244A2 (en) 2006-11-20 2008-05-29 The Trustees Of Columbia University In The City Of New York Phosphoinositide modulation for the treatment of neurodegenerative diseases
EP2112145A1 (en) 2008-04-24 2009-10-28 AxoGlia Therapeutics S.A. Chromenone derivatives useful for the treatment of neurodegenerative diseases
WO2010134082A1 (en) 2009-05-21 2010-11-25 Proteologics Ltd Chromenone derivatives for treatment of cancer
US8399460B2 (en) * 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives

Also Published As

Publication number Publication date
ES2530943T3 (es) 2015-03-09
IL219191A0 (en) 2012-06-28
UA107474C2 (uk) 2015-01-12
ECSP12011838A (es) 2012-06-29
US20110098271A1 (en) 2011-04-28
US8399460B2 (en) 2013-03-19
CN104447657A (zh) 2015-03-25
AR078786A1 (es) 2011-11-30
EA020523B9 (ru) 2015-01-30
RS53813B1 (en) 2015-06-30
US9029374B2 (en) 2015-05-12
PE20130149A1 (es) 2013-03-10
DOP2012000124A (es) 2012-07-15
EA201200618A1 (ru) 2012-12-28
EP2493870B1 (en) 2014-12-17
MY179833A (en) 2020-11-17
HRP20150146T1 (hr) 2015-05-22
KR20120098724A (ko) 2012-09-05
NZ599457A (en) 2014-04-30
HK1174027A1 (zh) 2013-05-31
EP2493870A1 (en) 2012-09-05
CU20120069A7 (es) 2012-10-15
BR112012010124B8 (pt) 2021-05-25
SA110310808B1 (ar) 2013-11-24
TW201121960A (en) 2011-07-01
JP5657010B2 (ja) 2015-01-21
SI2493870T1 (sl) 2015-03-31
KR101738195B1 (ko) 2017-05-19
MX2012005027A (es) 2012-09-07
CA2776994A1 (en) 2011-05-05
CL2012001056A1 (es) 2012-10-05
IN2012DN03328A (zh) 2015-10-23
US20130158026A1 (en) 2013-06-20
WO2011051704A1 (en) 2011-05-05
CY1116143T1 (el) 2017-02-08
ME02050B (me) 2015-05-20
EA020523B1 (ru) 2014-11-28
CR20120217A (es) 2012-06-28
PL2493870T3 (pl) 2015-04-30
CA2776994C (en) 2017-10-31
US20140194419A1 (en) 2014-07-10
SMT201500036B (it) 2015-05-05
CN102712615A (zh) 2012-10-03
CO6541528A2 (es) 2012-10-16
AU2010311107B9 (en) 2014-06-19
NI201200081A (es) 2012-11-07
CN102712615B (zh) 2014-12-17
GT201200126A (es) 2014-03-03
BR112012010124B1 (pt) 2021-02-17
US20160060240A1 (en) 2016-03-03
CN104447657B (zh) 2016-08-17
AU2010311107B2 (en) 2014-03-27
US20160272607A1 (en) 2016-09-22
JP2015078202A (ja) 2015-04-23
UY32978A (es) 2011-05-31
PT2493870E (pt) 2015-02-18
HN2012000889A (es) 2015-08-03
US8673906B2 (en) 2014-03-18
DK2493870T3 (en) 2015-02-23
BR112012010124A2 (pt) 2016-06-07
JP5872016B2 (ja) 2016-03-01
JP2013508449A (ja) 2013-03-07
US9718800B2 (en) 2017-08-01
AU2010311107A1 (en) 2012-05-03
TWI483939B (zh) 2015-05-11

Similar Documents

Publication Publication Date Title
HK1206335A1 (zh) 具有抗腫瘤活性的色烯酮衍生物
HK1173142A1 (zh) -磺酰基- -氟代嘧啶酮衍生物
HK1172893A1 (zh) -氟嘧啶酮衍生物
ZA201203205B (en) Benzimidazole-imidazole derivatives
IL216007A0 (en) Isoxazole-pyridine derivatives
ZA201106855B (en) Oxasiazole derivatives
IL215109A0 (en) Isoxazole-pyridazine derivatives
IL214941A0 (en) Isoxazole-pyrazole derivatives
ZA201104991B (en) Deoxyactagardine derivatives
HK1172894A1 (zh) -酰基- -氟嘧啶酮衍生物
HK1169623A1 (zh) 吡嗪並氮雜氧雜環庚烷衍生物
EP2512482A4 (en) DERIVATIVES OF 2-ALDOXIMINO-5-FLUOROPYRIMIDINE
ZA201104279B (en) Tetrahydronaphthalen-2-ol derivatives
GB0912499D0 (en) Indopyl-pyridone derivatives